BioWorld

Jan. 14, 2009

ZymoGenetics Soars 26% on $1.1B HCV Drug Deal with BMS

ZymoGenetics Inc.'s stock leaped 26 percent Tuesday on the news that it signed a deal potentially worth more than $1.1 billion with pharma giant Bristol-Myers Squibb Co. to develop and commercialize the Seattle-based biotech's early-stage hepatitis C drug. (BioWorld Today) Read More

Medicines to Acquire Targanta; Deal Staged from $42M to $138M

Innate, Adaptive Immune System: More in Common than Thought

Apitope, Merck Collaborating in $203M Deal for MS Drug

Antisoma's ASA404 Starts 2nd Phase III Study in Lung Cancer

Dimon Argues for Some Form of Universal Health Care in U.S.

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...